Correlations of growth hormone (GH) and insulin-like growth factor I (IGF-I): effects of exercise and abuse by athletes

被引:31
作者
De Palo, EF
Gatti, R
Lancerin, F
Cappellin, E
Spinella, P
机构
[1] Univ Padua, Sch Med, Dept Med Diagnost Sci & Special Therapies, Clin Biochem Sect, I-35128 Padua, Italy
[2] Azienda Osped Padova, Dept Med & Surg Sci, Padua, Italy
[3] Univ Padua, Dept Clin & Expt Med, Padua, Italy
关键词
growth hormone; insulin-like growth factor I(IGF-I); growth hormone binding protein (GHBP); insulin-like growth hormone binding proteins (IGFBPs); doping;
D O I
10.1016/S0009-8981(01)00378-3
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The importance of hormones on body metabolism when physical exercise is carried out has been established for a long time. Growth hormone (GH) is crucial in energy metabolism as well as in body anabolism. Recent studies have increased our knowledge of GH's mechanisms of action. In particular, insulin-like growth factor I (IGF-I), the main hormone mediating the principal GH effects and other protein structures (i.e, the binding proteins related to these two hormones), has been recognized as playing a crucial role. The biochemical aspects relating to the molecules of the GH/IGF-I axis have been described here. Furthermore, the belief that GH and IGF-I enhance performance has induced an 'abuse' of GH land possibly of IGF-I) by competitive sports athletes and amateurs. The present study outlines the best methods available to uncover abuse, as well as a series of potential research projects to recognize doping. The review also underlines the principal variables measurable in the laboratory and summarizes published reference ranges of these parameters. These biochemical and laboratory profiles describe principal experimental approaches, with the hope that this will stimulate new ideas on the subject of detecting doping practices. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1 / 17
页数:17
相关论文
共 69 条
[1]   Isotopic differences in human growth hormone preparations [J].
Abramson, FP ;
Osborn, BL ;
Teffera, Y .
ANALYTICAL CHEMISTRY, 1996, 68 (11) :1971-1972
[2]  
Andersen M, 1998, CLIN CHEM, V44, P1032
[3]   Growth hormone heterogeneity in human pituitary and plasma [J].
Baumann, G .
HORMONE RESEARCH, 1999, 51 :2-6
[4]   GROWTH-HORMONE HETEROGENEITY - GENES, ISOHORMONES, VARIANTS, AND BINDING-PROTEINS [J].
BAUMANN, G .
ENDOCRINE REVIEWS, 1991, 12 (04) :424-449
[5]  
BAXTER RC, 1995, CLIN BIOCHEM REV, V16, P91
[6]   The future of doping control in athletes - Issues related to blood sampling [J].
Birkeland, KI ;
Hemmersbach, P .
SPORTS MEDICINE, 1999, 28 (01) :25-33
[7]  
BLUM WF, 1993, J CLIN ENDOCR METAB, V76, P1610, DOI 10.1210/jc.76.6.1610
[8]   Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis [J].
Boonen, S ;
Mohan, S ;
Dequeker, J ;
Aerssens, J ;
Vanderschueren, D ;
Verbeke, G ;
Broos, P ;
Bouillon, R ;
Baylink, DJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (12) :2150-2158
[9]   Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women [J].
Butterfield, GE ;
Thompson, J ;
Rennie, MJ ;
Marcus, R ;
Hintz, RL ;
Hoffman, AR .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1997, 272 (01) :E94-E99
[10]  
Cappellin E, 1999, CLIN CHEM, V45, P443